Last reviewed · How we verify
Biosolution Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Autologous cultured keratinocyte cell | Autologous cultured keratinocyte cell | phase 3 | Cell therapy | Dermatology |
Therapeutic area mix
- Dermatology · 1
- Orthopedics / Regenerative Medicine · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Bone Therapeutics S.A · 1 shared drug class
- Brainstorm-Cell Therapeutics · 1 shared drug class
- Celavie Bioscences, LLC · 1 shared drug class
- China Spinal Cord Injury Network · 1 shared drug class
- City of Hope Medical Center · 1 shared drug class
- DiscGenics, Inc. · 1 shared drug class
- Dr. Grant M. Pagdin · 1 shared drug class
- Avicenna Research Institute · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Biosolution Co., Ltd.:
- Biosolution Co., Ltd. pipeline updates — RSS
- Biosolution Co., Ltd. pipeline updates — Atom
- Biosolution Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Biosolution Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biosolution-co-ltd. Accessed 2026-05-13.